BioSpace News Archive

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, continues to exhibit a leading presence at the Cutting Edge of Transplantation Meeting, February 25-27, 2021, with leading institutions sharing AlloSure donor-derived cell-free DNA data in both poster presentations and symposium.

Reductions in Debt Principal and Interest Rate Further Strengthen Balance Sheet, Support Ongoing Efforts to Best Position Company for Significant CDMO Business Growth

Company’s PANTHER technology platform enables selective targeted delivery of therapeutic compounds directly to neutrophils and other immune cells

To perform patient-specific eye surgery planning, dramatically improve vision and treat astigmatism, Optimo Medical AG and Ansys are incorporating high-fidelity structural simulations with cutting-edge digital twin technology into next-generation surgery preparation.

- Phase 3 GENESIS study in stem-cell mobilization (SCM) showed statistically significant positive results for primary endpoint in interim analysis; enrollment ceased early; top-line data expected early Q2 2021 -

Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the addition of three seasoned pharmaceutical leaders, Kathy He , Richard Lee , MD, and Dana Zhang , MD, to its expanding team.

Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. study activities expected to expand the study to a total of 8 countries and approximately 40 recruiting sites; Top-line results expected in the second quarter

Bristol Myers Squibb to Participate in Raymond James Virtual 42 nd Annual Institutional Investors Conference

OKYO Pharma Limited, a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and chronic ocular pain, announced that patent No. 10,899,796 entitled “Compounds and Methods for Treating Pain” was issued by the United States Patent and Trademark Office on January 26, 2021.

GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation, a leader in molecular diagnostics and precision medicine, announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.